Dr McCreight is a Medical Registrar specialising in Diabetes and Endocrinology and General Internal Medicine.
Laura is currently working as a Clinical Research Fellow in the Division of Molecular and Clinical Medicine with Professor Ewan Pearson’s team.
During her time in the department she is working towards her PhD researching “Pharmacokinetics and Biological Mechanisms in Drug Outcomes in Type 2 Diabetes Mellitus”.
Laura’s research focuses on drug outcomes in Type 2 Diabetes. She is running three clinical studies (listed below), as well as working with cellular models of drug response.
- Pharmacokinetics of Metformin Intolerance
A PK study of phenotypically intolerant vs tolerant individuals to compare lactic acid and metformin concentrations post-metformin administration in the two cohorts.
- Impact of OCT1 Genotype and OCT1 Inhibiting Drugs on an Individual’s Tolerance of Metformin.
A “recruit by genotype”, double-blind, placebo-controlled crossover study, to compare the metformin tolerance of OCT1 wild type and null non-diabetic individuals, during exposure to omeprazole or placebo.
- Response of Individual’s with Ataxia-Telangiectasia to Metformin and Pioglitazone.
This crossover study compares individuals with AT to those without, during treatment with, firstly, metformin, followed by pioglitazone. Comparison will be made in changes in glucose handling using dual-tracer mixed meal tests. Other investigations include fat biopsy, blood and urine sampling and an abdominal MRI for fat distribution.
Metformin and the gastrointestinal tract.McCreight LJ, Bailey CJ, Pearson ER.Diabetologia. 2016 Mar;59(3):426-35. tRNA methyltransferase homologue gene TRMT10A mutation in young adult-onset diabetes with intellectual disability, microcephaly and epilepsy.Yew TW, McCreight L, Colclough K, Ellard S, Pearson ER.Diabet Med. 2015 Nov 3. How safe are DPP4 inhibitors?McCreight LJ, Fisher M.Practical Diabetes, 2013 Nov 30 (9) 352–353.